Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zilucoplan (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RAISE-XT
  • Sponsors Ra Pharmaceuticals; UCB Biopharma

    • Most Recent Events

    • 11 Oct 2024 According to an UCB media release, data from this study will be presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session taking place between October 15 - 18, 2024 at the Savannah Convention Center in Georgia, U.S.
    • 31 May 2024 Planned End Date changed from 20 May 2026 to 2 Jun 2026.
    • 31 May 2024 Planned primary completion date changed from 20 May 2026 to 2 Jun 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top